title: Study of the Urinary Ratio of 6 beta-Hydroxycortisol/Cortisol as a Biomarker of CYP3A4 Activity in Egyptian Patients with Chronic Liver Diseases.
abstract: The urinary ratio of 6 beta-hydroxycortisol/cortisol (6 beta-OHC/C) as a biomarker of CYP3A4 metabolizing activity has been studied in Egyptian patients with chronic liver cirrhosis associated with previous hepatic Schistosomiasis infection to determine any possible alteration in enzyme activity. The ratio of 6-beta OHC/C was determined in morning urine samples collected from 8:00 a.m. to 12:00 p.m. in healthy adults (n = 36) and patients with liver cirrhosis (n = 57). The median age for control was 27 years (range: 18-50 years) and 50 years (range: 27-75 years) for patients. 6 beta-OHC was detected in urine by ELIZA kits (Stabiligen, France). Patients with liver cirrhosis were categorized according to Child Pugh Classification into Child B (n = 28) and Child C (n = 29) classes. Cholestasis was observed in 9/28 of Child B class and 8/29 of Child C class of patients. The control subjects showed gender-related difference in the urinary ratio of 6 beta-OHC/C. A significant reduction (P < 0.001) in 6 beta-OHC/C ratio was observed only in Child C patients in comparison with control subjects. Regression analysis showed a significant correlation (P < 0.05) between 6 beta-OHC/C ratio and serum albumin. The influence of cholestasis on the urinary ratio of 6-beta OHC/C was observed on cirrhotic patients of Child B class. In conclusion, patients with chronic liver cirrhosis might have a reduction of metabolizing activity of CYP3A4 enzymes which could be identified by measuring the urinary ratio of 6 beta-OHC/C. This reduction is more apparent in severe liver injury (Child C class). Therefore, it is important to understand the metabolic fate of drugs metabolized by 3A4 enzymes in patients with liver cirrhosis to avoid drug accumulation that might lead to development of drug toxicity.
authors.affiliation: Pharmacology Dept, Faculty of Medicine, Assiut University, Assiut, Egypt.
authors.forename: Ehab S
authors.initials: ES
authors.lastname: Eldesoky
authors.forename: Sherif I
authors.initials: SI
authors.lastname: Kamel
authors.forename: Ahlam M
authors.initials: AM
authors.lastname: Farghaly
authors.forename: Madiha Y
authors.initials: MY
authors.lastname: Bakheet
authors.forename: Mohsen A
authors.initials: MA
authors.lastname: Hedaya
authors.forename: Jean-Pascal
authors.initials: JP
authors.lastname: Siest
references.citation: Annu Rev Pharmacol Toxicol. 1998;38:389-430
references.pmid: 9597161
references.citation: J Pharmacol Exp Ther. 1994 Oct;271(1):549-56
references.pmid: 7965755
references.citation: FASEB J. 1992 Jan 6;6(2):745-8
references.pmid: 1537465
references.citation: Br J Clin Pharmacol. 2003 Jan;55(1):86-93
references.pmid: 12534644
references.citation: Pharmacogenetics. 2000 Apr;10(3):187-216
references.pmid: 10803676
references.citation: J Pharmacol Exp Ther. 1997 Jul;282(1):391-6
references.pmid: 9223579
references.citation: Clin Endocrinol (Oxf). 2006 Jan;64(1):37-45
references.pmid: 16402926
references.citation: Drug Metab Dispos. 2002 Oct;30(10):1108-14
references.pmid: 12228187
references.citation: Pharmacogenetics. 2000 Jul;10(5):373-88
references.pmid: 10898107
references.citation: Ther Drug Monit. 2002 Dec;24(6):722-7
references.pmid: 12451288
references.citation: Drug Metab Rev. 1997 Feb-May;29(1-2):413-580
references.pmid: 9187528
references.citation: J Clin Pharmacol. 2004 Dec;44(12):1412-7
references.pmid: 15545313
references.citation: Can J Physiol Pharmacol. 2000 Nov;78(11):912-9
references.pmid: 11100940
references.citation: Hepatol Res. 2003 May;26(1):28-33
references.pmid: 12787801
references.citation: Br J Clin Pharmacol. 2002 Feb;53(2):203-6
references.pmid: 11851646
references.citation: Steroids. 2004 Jan;69(1):67-70
references.pmid: 14715379
references.citation: Liver. 2000 Jul;20(4):281-9
references.pmid: 10959806
references.citation: Pharmacogenetics. 2004 Oct;14(10):635-45
references.pmid: 15454728
references.citation: Clin Transplant. 2004 Apr;18(2):124-9
references.pmid: 15016124
references.citation: J Pharmacokinet Biopharm. 1996 Oct;24(5):475-90
references.pmid: 9131486
references.citation: Eur J Clin Pharmacol. 2003 Dec;59(10):713-33
references.pmid: 14605790
references.citation: Hepatology. 1995 Jan;21(1):120-8
references.pmid: 7806144
references.citation: Clin Pharmacol Ther. 1999 Sep;66(3):224-31
references.pmid: 10511057
references.citation: Pharmacogenetics. 2001 Dec;11(9):773-9
references.pmid: 11740341
references.citation: Clin Pharmacol Ther. 1993 Dec;54(6):621-9
references.pmid: 8275617
references.citation: J Pharmacol Exp Ther. 1994 Jul;270(1):414-23
references.pmid: 8035341
references.citation: Pharmacol Res. 2005 Jun;51(6):575-80
references.pmid: 15829439
references.citation: Clin Biochem. 1995 Feb;28(1):49-54
references.pmid: 7720227
references.citation: Drug Metab Pharmacokinet. 2002;17(6):522-31
references.pmid: 15618707
references.citation: Am J Physiol Gastrointest Liver Physiol. 2005 Jan;288(1):G74-84
references.pmid: 15331348
references.citation: J Clin Pharmacol. 2001 Jul;41(7):723-31
references.pmid: 11452704
references.citation: J Clin Oncol. 2002 Sep 1;20(17):3683-90
references.pmid: 12202670
references.citation: Nat Med. 2001 Mar;7(3):285-7
references.pmid: 11231620
references.citation: Nephron. 1976;16(1):31-41
references.pmid: 1244564
references.citation: J Hepatol. 1997 Feb;26(2):236-43
references.pmid: 9059941
references.citation: Clin Chim Acta. 1986 Jun 30;157(3):267-76
references.pmid: 3731488
references.citation: Clin Pharmacol Ther. 1992 Jan;51(1):18-23
references.pmid: 1732074
references.citation: Cancer. 1996 Apr 15;77(8):1427-33
references.pmid: 8608525
references.citation: Drug Metab Dispos. 2006 May;34(5):756-64
references.pmid: 16455805
references.citation: Toxicol Appl Pharmacol. 2004 Sep 15;199(3):193-209
references.pmid: 15364537
references.citation: Cancer Epidemiol Biomarkers Prev. 2001 Mar;10(3):237-42
references.pmid: 11303593
references.citation: Br J Clin Pharmacol. 2006 Feb;61(2):200-10
references.pmid: 16433874
references.citation: Mol Pharmacol. 2002 Jul;62(1):162-72
references.pmid: 12065767
references.citation: Clin Biochem. 2005 Jun;38(6):531-4
references.pmid: 15885232
references.citation: J Med Virol. 1995 Apr;45(4):423-8
references.pmid: 7545213
references.citation: Acta Physiol Hung. 2003;90(3):217-23
references.pmid: 14594192
references.citation: J Clin Pharmacol. 2002 Dec;42(12):1374-9
references.pmid: 12463733
references.citation: J Clin Pharmacol. 1999 Jun;39(6):578-82
references.pmid: 10354961
references.citation: Hepatology. 1994 Jun;19(6):1513-20
references.pmid: 8188183
references.citation: J Pharmacol Exp Ther. 1994 Oct;271(1):557-66
references.pmid: 7965756
references.citation: Clin Pharmacol Ther. 1992 Sep;52(3):265-73
references.pmid: 1526083
references.citation: Biochim Biophys Acta. 2005 Feb 21;1687(1-3):84-93
references.pmid: 15708356
references.citation: Drug Metab Dispos. 2003 Nov;31(11):1283-7
references.pmid: 14570755
references.citation: Hepatology. 1994 Apr;19(4):933-40
references.pmid: 8138268